After initial results, many researchers maintain lower frequency protocols rather than stopping entirely
In September 2023 the FDA placed BPC-157 in Category 2 of its 503A interim bulk-substances policy, citing immunogenicity and peptide-characterization concerns, effectively excluding it from the 503A compounding bulk-substances list
After deduplication and standardization, the final UC-related targets were obtained
This Koi Peptides review covers 99%+ purity, per-lot COAs, ISO 17025 lab testing, US sourcing, pricing, and what buyers can verify in 2026
Because a large number of comparisons were performed on the relative abundance data, main effect results from these analyses also underwent a BenjaminiHochberg false discovery rate (FDR) correction for multiple comparisons, and instances where a result was significant after this correction have been duly noted
Natural options can have a mild anti-androgenic effect, and some have a decent single study behind them, but none comes close to finasteride or dutasteride